11c-sarcosine
Major Depressive Disorder
All India Institute of Medical Sciences, BhubaneswarradiopharmaceuticalPhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 65/ 100
Competitive context
129 Active assets in the Major Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
(1S,2R)-MILNACIPRAN Allergan | Phase 4 | BBB |
Opc-34712 Nova Scotia Health Authority | Phase 4 | BBB |
Vortioxetine Mayo Clinic | Phase 4 | BBB |
S-Ketamine Shanghai Mental Health Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
11c-sarcosine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →